I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Switzerland

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology Skin Cancer

Skin Cancer

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Jun 1 / Roche and Genentech
Atezolizumab, cobimetinib, and vemurafenib in patients with BRAFV600 mutation-positive melanoma with central nervous system metastases: Final results and exploratory biomarker analysis from the phase 2 TRICOTEL study
The phase 2 TRICOTEL study evaluated atezolizumab plus cobimetinib plus vemurafenib in a BRAFV600 wild-type cohort and a BRAFV600 mutation-positive melanoma with CNS metastases cohort. This poster presents the final analysis results and exploratory biomarker analyses for patients with BRAFV600-mutated melanoma treated with the triplet therapy combination.
Oncology Skin Cancer ASCO-2024

Sign up or login to unlock the full suite of MEDICALLY features
Independent content
Sep 30 / Springer Healthcare
European Society for Medical Oncology ESMO 2022 Annual Meeting: Melanoma
The Annual Meeting of the European Society of Medical Oncology (ESMO) was a hybrid meeting, with delegates attending in person for the first time since before the pandemic.
Oncology Skin Cancer ESMO-2022
Bookmark this
Share page

Sign up or login to unlock the full suite of MEDICALLY features
Sep 10 / Roche and Genentech
A Phase 1b/2 Multicenter, Randomized, Umbrella Study Evaluating Novel Treatment Combinations in Melanoma (MORPHEUS-MELANOMA)
This poster describes the design of a phase 1b/2 multicenter, randomized, open-label, umbrella study (MORPHEUS-MELANOMA) to evaluate the safety, efficacy, and pharmacokinetics of various novel treatments or treatment combinations targeting multiple immune evasion mechanisms in patients with treatment-naive, resectable stage III melanoma and in patients with previously treated stage IV melanoma.
Oncology Skin Cancer Melanoma ESMO-2022

Sign up or login to unlock the full suite of MEDICALLY features
Sep 10 / Roche and Genentech
Time to Development of Central Nervous System Metastases With Atezolizumab or Placebo Combined With Vemurafenib + Cobimetinib: Updated Results From the Phase 3 IMspire150 Study
The phase 3 IMspire150 study demonstrated improved progression-free survival with first-line combination treatment with the combination of atezolizumab, vemurafenib, and cobimetinib compared with placebo, vemurafenib, and cobimetinib in patients with previously untreated BRAFV600 mutation–positive advanced melanoma. This poster describes results of an exploratory analysis to evaluate incidence and time to development of CNS metastases in the IMspire150 study.
Oncology Skin Cancer Melanoma ESMO-2022

Sign up or login to unlock the full suite of MEDICALLY features
Jun 4 / Roche and Genentech
Overall Survival (OS) With First-Line Atezolizumab or Placebo in Combination With Veruraenib and Cobimetinib in BRAFV600 Mutation-Positive Advanced Melanoma: Second Interim OS Analysis of the Phase 3 IMspire150 Study
Primary analysis of the phase 3 IMspire150 study (NCT02908672) demonstrated improved investigator-assessed progression-free survival (PFS) with first-line atezolizumab + vemurafenib + cobimetinib (A + V + C) versus placebo + vemurafenib + cobimetinib (P + V + C) in patients with previously untreated BRAFV600 mutation–positive advanced melanoma (hazard ratio [HR] 0.78; 95% CI, 0.63-0.97; P=0.025)1.
Oncology Skin Cancer ASCO-2022

Sign up or login to unlock the full suite of MEDICALLY features
Dec 2 / Roche and Genentech
Systematic Literature Review and Network Meta-Analysis of Immunotherapy, Targeted Agents or Combination Regimens in Treatment-Naïve Unresectable or Metastatic Melanoma
This systematic literature review and network meta-analysis compared the safety and efficacy of atezolizumab plus cobimetinib plus vemurafenib (ACV) to other therapies for treatment-naive adults with unresectable or metastatic melanoma and found that ACV had the highest PFS benefit and a low rate of treatment discontinuation compared to other therapies.
Oncology Skin Cancer ISPOR-EU-2021

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.